Abstract
To investigate the long-term psychological and physiological outcomes of muscle dysmorphia (MD) and the misuse of anabolic androgenic steroids (AAS) and performance-enhancing drugs (PEDs) in a Turkish male over two decades. Conducted a retrospective case review, including medical record analysis, psychological evaluations, and physical examinations to document the progression and consequences of MD and substance abuse. The patient demonstrated persistent MD symptoms, compounded by continuous AAS and PED use, leading to severe health complications such as cardiac hypertrophy and endocrine disorders. The case highlights the necessity for early identification, intervention, and preventive approaches to address MD and PED abuse. It stresses the importance of ongoing surveillance and research to develop effective public health policies.
References
- Baggish A L, Weiner R B, Kanayama G, Hudson J I, Lu M T, Hoffmann U & Pope Jr H G. (2017). Cardiovascular toxicity of illicit anabolic-androgenic steroid use. Circulation. 2017;135(21): 1991-2002. https://doi. org/10.1161/CIRCULATIONAHA.116.026945
- Bonnecaze A K, O’Connor T & Burns C A. (2021). Harm reduction in male patients actively using anabolic androgenic steroids (AAS) and performance-enhancing drugs (PEDs): a review. J Gen Intern Med. 2021;36(7):2055-2064. https://doi.org/10.1007/s11606-021-06751-3
- Olivardia R, Pope Jr H G & Hudson J I. (2002). Muscle dysmorphia in male weightlifters: A case-control study. Am J Psychiatry. 2000;157(8):1291-1296. https://doi.org/10.1176/appi.ajp.157.8.1291
- Pope C G, Pope H G, Menard W, Fay C, Olivardia R & Phillips K A. (2005). Clinical features of muscle dysmorphia among males with body dysmorphic disorder. Body image. 2005;2(4): 395-400. https://doi.org/10.1016/j.bodyim.2005.09.001
- Van Amsterdam J, Opperhuizen A & Hartgens F. (2010). Adverse health effects of anabolic– androgenic steroids. Regul Toxicol Pharmacol. 2010;57(1):117-123. https://doi.org/10.1016/j.yrtph.2010.02.001
Abstract
Bu çalışma, son yirmi yıllık süre zarfında bir Türk erkeğinde görülen kas dismorfisi (KD) ve anabolik androjenik steroid (AAS) ile performans arttırıcı ilaçların (PAİ) sürekli kullanımının psikolojik ve fizyolojik etkilerini araştırmayı hedeflemiştir. KD ve madde kullanımının evrimini ve sonuçlarını belgelemek amacıyla hasta tıbbi kayıtlarının retrospektif analizi, psikolojik değerlendirmeler ve fiziksel muayeneler yapılmıştır. Hastanın devamlı AAS ve PAİ kullanımı sonucunda kalıcı KD semptomları ve kalp büyümesi, hormonal dengesizlikler gibi ciddi sağlık sorunları ortaya çıkmıştır. Bu olgu sunumu, KD ile birlikte gelen AAS ve PED kötüye kullanımına karşı erken tanı, müdahale ve önleyici stratejilerin önemini ortaya koymaktadır. Ayrıca, etkili kamu sağlığı politikalarının oluşturulmasına yönelik kapsamlı araştırma ve sürekli izlemenin gerekliliğini vurgulamaktadır.
Keywords
Kas dismorfisi anabolik steroid kötüye kullanımı performansı artırıcı ilaç kötüye kullanımı
References
- Baggish A L, Weiner R B, Kanayama G, Hudson J I, Lu M T, Hoffmann U & Pope Jr H G. (2017). Cardiovascular toxicity of illicit anabolic-androgenic steroid use. Circulation. 2017;135(21): 1991-2002. https://doi. org/10.1161/CIRCULATIONAHA.116.026945
- Bonnecaze A K, O’Connor T & Burns C A. (2021). Harm reduction in male patients actively using anabolic androgenic steroids (AAS) and performance-enhancing drugs (PEDs): a review. J Gen Intern Med. 2021;36(7):2055-2064. https://doi.org/10.1007/s11606-021-06751-3
- Olivardia R, Pope Jr H G & Hudson J I. (2002). Muscle dysmorphia in male weightlifters: A case-control study. Am J Psychiatry. 2000;157(8):1291-1296. https://doi.org/10.1176/appi.ajp.157.8.1291
- Pope C G, Pope H G, Menard W, Fay C, Olivardia R & Phillips K A. (2005). Clinical features of muscle dysmorphia among males with body dysmorphic disorder. Body image. 2005;2(4): 395-400. https://doi.org/10.1016/j.bodyim.2005.09.001
- Van Amsterdam J, Opperhuizen A & Hartgens F. (2010). Adverse health effects of anabolic– androgenic steroids. Regul Toxicol Pharmacol. 2010;57(1):117-123. https://doi.org/10.1016/j.yrtph.2010.02.001
Details
| Primary Language | English |
|---|---|
| Subjects | Drug Addiction Consultancy, Behavioural Epigenetics, Clinical Psychology |
| Journal Section | Research Articles |
| Authors | |
| Publication Date | July 26, 2024 |
| Submission Date | March 9, 2024 |
| Acceptance Date | May 14, 2024 |
| Published in Issue | Year 2024 Volume: 3 Issue: 2 |
